ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Adaptive Induction Therapy in Renal Transplant Recipients (RTR) with Donor-Specific Antibody (DSA)

K. Linhares1, M. Cristelli2, R. De Marco3, L. Viana2, C. Felipe2, M. Tavares2, C. Peixoto2, G. Marcello2, J. Toniato2, K. Ficher2, L. Villanueva2, L. Villanueva2, M. De Lima3, J. Pestana2, H. Tedesco Jr.2

1Nephrology Division, Hospital do Rim, Sao Paulo, Brazil, 2Nephrology Division, Hospital Do Rim, Sao Paulo, Brazil, 3Histocompatibility Laboratory, Instituto De Imunogenética IGEN, Sao Paulo, Brazil

Meeting: 2020 American Transplant Congress

Abstract number: D-005

Keywords: Kidney transplantation

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Kidney Immunosuppression: Induction Therapy

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
  • Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).

*Purpose: Patients with preformed DSA are at higher risk of developing acute antibody-mediated rejection (ABMR) after kidney transplantation.

*Methods: We analyzed consecutive kidney transplant recipients (RTR) with pretransplant negative DSA for loci A, B and DR and negative cytotoxicity crossmatch from May 2017 to November 2018 in a single center cohort. All patients received induction therapy with single 3mg/Kg dose rATG and maintenance immunosuppression with tacrolimus, sodium mycophenolate and prednisone. Additional test for anti C, DQ and DP DSA was performed in sensitized patients (Panel Reactive Antibody>0) followed by flow cytometry cross match (FCXM). Patients with positive FCXM received complementary induction with 5 sessions of plasmapheresis (PF) and IVIG, according to the type and strength of DSA. This preliminary analysis describes the incidence of treated acute rejection (tRA) during the first year of transplantation.

*Results: From May 15, 2017 to November 28, 2018, 1.464 kidney transplants were performed. Of these, 59 patients (4%) had a first post-transplant day DSA >1.500 for loci C, DQ or DP. Median class I and class II PRA was 59% and 27%. The FCXM was T-/B- in 32 (54.2%), T-/B+ in 21 (35.6%) and T+/B+ in 6 (10.2%) patients. Nine (43) patients with T-/B+ and 1 (17%) patients with T+/B+ received PF+IVIG. AMBR occurred in 1 patient with T-/B- and in 1 patient with T+/B+. Overall incidence of tRA was 16% for T-/B- (1 clinical, 2 borderline, 1 1A and 1 ABMR), 38% for T-/B+ (2 clinical, 6 borderline), and 33% for T+/B+ (1 borderline and 1 ABMR).

*Conclusions: This analysis suggests that DSA screening followed by FCXM allows the use of individualized reduced intensity induction therapy.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Linhares K, Cristelli M, Marco RDe, Viana L, Felipe C, Tavares M, Peixoto C, Marcello G, Toniato J, Ficher K, Villanueva L, Villanueva L, Lima MDe, Pestana J, Jr HTedesco. Adaptive Induction Therapy in Renal Transplant Recipients (RTR) with Donor-Specific Antibody (DSA) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/adaptive-induction-therapy-in-renal-transplant-recipients-rtr-with-donor-specific-antibody-dsa/. Accessed March 8, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.